Literature DB >> 23075067

N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.

Victor Hernandez-Olmos1, Aliaa Abdelrahman, Ali El-Tayeb, Diana Freudendahl, Stephanie Weinhausen, Christa E Müller.   

Abstract

P2X4 receptor antagonists have potential as drugs for the treatment of neuropathic pain and neurodegenerative diseases. In the present study the discovery of phenoxazine derivatives as potent P2X4 antagonists is described. N-Substituted phenoxazine and related acridone and benzoxazine derivatives were synthesized and optimized with regard to their potency to inhibit ATP-induced calcium influx in 1321N1 astrocytoma cells stably transfected with the human P2X4 receptor. In addition, species selectivity (rat, mouse, human) and receptor subtype selectivity (versus P2X1,2,3,7) were investigated. The most potent P2X4 antagonist of the present series was N-(benzyloxycarbonyl)phenoxazine (26, PSB-12054) with an IC(50) of 0.189 μM and good selectivity versus the other human P2X receptor subtypes. N-(p-Methylphenylsulfonyl)phenoxazine (21, PSB-12062) was identified as a selective P2X4 antagonist that was equally potent in all three species (IC(50): 0.928-1.76 μM). The compounds showed an allosteric mechanism of action. The present study represents the first structure-activity relationship analysis of P2X4 antagonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075067     DOI: 10.1021/jm300845v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

Review 1.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

2.  Synthesis, characterization, and in vitro evaluation of the selective P2Y2 receptor antagonist AR-C118925.

Authors:  Muhammad Rafehi; Joachim C Burbiel; Isaac Y Attah; Aliaa Abdelrahman; Christa E Müller
Journal:  Purinergic Signal       Date:  2016-10-20       Impact factor: 3.765

3.  Shear stress modulates endothelial KLF2 through activation of P2X4.

Authors:  R Sathanoori; F Rosi; B J Gu; J S Wiley; C E Müller; B Olde; D Erlinge
Journal:  Purinergic Signal       Date:  2015-01-08       Impact factor: 3.765

Review 4.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

5.  Dandamycin and chandrananimycin E, benzoxazines from Streptomyces griseus.

Authors:  Emma C Barnes; Patricia Bezerra-Gomes; Markus Nett; Christian Hertweck
Journal:  J Antibiot (Tokyo)       Date:  2015-02-18       Impact factor: 2.649

6.  Investigation on 2',3'-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists.

Authors:  Diego Dal Ben; Michela Buccioni; Catia Lambertucci; Gabriella Marucci; Andrea Spinaci; Anna Marchenkova; Aliaa Abdelrahman; Andrea Nistri; Christa E Müller; Rosaria Volpini
Journal:  ACS Med Chem Lett       Date:  2018-12-26       Impact factor: 4.345

7.  Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor.

Authors:  Claudio Coddou; Rodrigo Sandoval; María José Hevia; Stanko S Stojilkovic
Journal:  Neurosci Lett       Date:  2018-10-23       Impact factor: 3.046

8.  ATP Evokes Ca2+ Responses and CXCL5 Secretion via P2X4 Receptor Activation in Human Monocyte-Derived Macrophages.

Authors:  Janice A Layhadi; Jeremy Turner; David Crossman; Samuel J Fountain
Journal:  J Immunol       Date:  2017-12-18       Impact factor: 5.422

Review 9.  Contribution of P2X4 receptor in pain associated with rheumatoid arthritis: a review.

Authors:  Nurul Ajilah Mohamed Khir; Ain' Sabreena Mohd Noh; Nazlahshaniza Shafin; Che Aishah Nazariah Ismail
Journal:  Purinergic Signal       Date:  2021-02-17       Impact factor: 3.765

Review 10.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.